{"schema_version":"secwatch.filing_event.v1","accession":"0001420720-25-000039","form_type":"8-K","ticker":"IBIO","cik":"0001420720","company_name":"iBio, Inc.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.370630+00:00","generated_at":"2026-05-16T21:00:07.889844+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"iBio Q1 FY2026 revenue $0.1M; cash $49.6M; IBIO-610 half-life up to 100 days","bullets":["Revenue $0.1M vs $0 prior year; R&D expenses $3.6M (up $2.3M YoY); G&A $2.5M (down $0.3M).","Cash $49.6M as of Sept 30, 2025, expected to fund operations into Q4 FY2027.","Closed $50M public offering; potential additional $50M from common warrant exercise for total up to $100M.","IBIO-610 NHP data shows predicted human half-life up to 100 days, enabling potential twice-yearly dosing.","Regained Nasdaq compliance on Nov 4, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001420720-25-000039","json":"https://secwatch.observer/filing/0001420720-25-000039.json","markdown":"https://secwatch.observer/filing/0001420720-25-000039.md","text":"https://secwatch.observer/filing/0001420720-25-000039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420720/000142072025000039/0001420720-25-000039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420720/000142072025000039/ibio-20251112x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T21:00:07.889844+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}